Funny how you shorts are sure a reverse split is coming.
I am waiting to see what news comes before the Nasdaq deadline is reached.
Now we start to see all the rationalization posts from the shorts.
Where are the shorts going to get shares if good news starts coming out?
Shorts have been unable to cover any significant amount since the Russell rebalancing.
Dedicated longs are not selling and there is very little institutional ownership.
Shorts were hoping that delisting would eliminate the need to cover.
Anybody who listened to the shareholders meeting knows that Dr Mullan has a plan and he obviously convinced Nasdaq the extension was appropriate.
The shorts can cry all they want but those are the facts!
As discussed in the shareholders meeting, Anatabloc moves through the body quickly which means the original formulation needs to be taken consistently, several times a day, in order for it to be most effective.
Obviously, the shorts are not happy about the information revealed the shareholders meeting. Formulation testing only taking about three months, including some additional efficiency data taken, is not consistent with the recent short seller spin.
Dr Mullan has a history of getting promising clinical trial studies funded.
Simply look into Archer Pharmaceuticals for an example.
The shorts don't want to talk about this.
With the discussion in the shareholders meeting about how quickly Anatabloc moves through the body, my guess is a lot of people who tried Anatabloc did not realize it needed to be taken consistently, several times a day, in order for it to be most effective.
The shorts keep harping about how long this will take but three months for formulation testing, including some additional efficiency data, is not consistent with the latest bashing.
I agree with your thoughts on securing financing. The discussion about Therapeutic targets was very compelling. I also think the data which has already been collected on Anatabloc will also be helpful in obtaining more financing.
Besides using that early data to help select the best Therapeutic targets, I believe that data will also be useful for helping to secure funding.
What I found especially compelling about the platform comment was the long list of potential Therapeutic targets that are associated with up-regulated NF-kb. That is a FIVE STAR list of Therapeutic targets!
If RCPI is successful in obtaining drug status on just one of those therapeutic targets, the company will be an enormous success, let alone if more than one of those potential targets is achieved.
This is obviously why Dr Mullan chose to become CEO of Rock Creek.
The opportunity of this molecule with it's impact on up-regulated NF-kb is just too enormous to pass up given the large number of potential therapeutic targets.
This is one reason why I believe Dr Mullan will not have a problem securing the necessary funding to complete the clinical trials. The size of this platform is just to large to ignore imho, especially when there are already dozens of ex-anatabloc users that have already used the product (although probably not in it's most effective formulation) and believe it has therapeutic benefit.
As Dr Mullan said, it is very unusual to have this much data already at this early stage of the drug regulatory process.
Here are couple of things I found on the Quotient Clinical web site today.
Clinical Trial Authorisation (CTA) applications to the MHRA, with an average approval time of just 15 days;
Quotient Clinical has extensive experience of pre-formulation and formulation development. We will help you find the optimal formulation choice for your molecule, using a wide range of proven, scalable formulation technologies, and for all routes of administration.
I think Dr Mullan said six different formulations will be tested in phase 1, with each taking about 2 weeks.
The train is about to leave the station.
After listening to the shareholders meeting again, here are some of the key points I heard.
I recommend all shareholders take the time to listen. There is a lot more information than this.
- Milestones have not changed since September
- Collating data for IND response and for CTA filing
- CTA filing expected in Dec
- Quotient Clinical working on new drug formulations with focus on time release
- Several new drug formulations being developed for testing
- CTA dosing studies on new formulations starting 1Q15 (phase 1)
- Besides normal phase 1 safety data some PD (efficiacy) data will be taken
- Only about 3 months needed to complete the dosing studies
- On to Phase II studies, using appropriate drug formulations for specific selected targets
- During Q&A, Dr. Mullan said the board is focused on the financing issue but could not discuss yet.
I agree Dr Mullan seemed to be holding back some, especially in regards to the funding efforts, but my guess is when the CTA and IND trials get underway, we will hear a lot more, and shouldn't be very long from now.